Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction

Similar documents
Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care

Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

Quality ID #443: Non-Recommended Cervical Cancer Screening in Adolescent Females National Quality Strategy Domain: Patient Safety

Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care

The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are:

DESCRIPTION: Percentage of women years of age who had a mammogram to screen for breast cancer

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #402: Tobacco Use and Help with Quitting Among Adolescents National Quality Strategy Domain: Community / Population Health

DESCRIPTION: The percentage of adolescent females years of age who were screened unnecessarily for cervical cancer

Quality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health

Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

DESCRIPTION: The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

DESCRIPTION: Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication

Measure #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care

Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health

Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Measure #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care

Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care

2018 CMS Web Interface

Quality ID #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care

Quality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged Years of Age National Quality Strategy Domain: Effective Clinical Care

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care

Quality ID #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination

Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination

DENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period

DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care

Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Measure #408: Opioid Therapy Follow-up Evaluation National Quality Strategy Domain: Effective Clinical Care

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care

DENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

DESCRIPTION: Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

This is a two-part measure which is paired with Measure #154: Falls: Risk Assessment.

Quality ID #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care

2019 CMS Web Interface

2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2018 CMS Web Interface

DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery

Quality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety

DENOMINATOR: All female patients aged 65 years and older with a diagnosis of urinary incontinence

Quality ID# 406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients National Quality Strategy Domain: Effective Clinical Care

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow

Strep Test 87070, 87071, 87081, Pharyngitis (CWP)

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Intermediate Outcome

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #342: Pain Brought Under Control Within 48 Hours National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

DENOMINATOR: All patients, regardless of age, with a diagnosis of inflammatory bowel disease who initiated an anti-tnf agent

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Measure #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Transcription:

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period INSTRUCTIONS: This measure is to be submitted a minimum of once per performance period for patients with a diagnosis of persistent asthma seen during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission: The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data. DENOMINATOR: Patients 5-64 years of age with persistent asthma and a visit during the measurement period DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for registry measures. Denominator Criteria (Eligible Cases): Patients aged 5-64 years on date of encounter AND Diagnosis for persistent asthma (ICD-10-CM): J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52 AND Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99381*, 99382*, 99383*, 99384*, 99385*, 99386*, 99387*, 99391*, 99392*, 99393*, 99394*, 99395*, 99396*, 99397* AND NOT DENOMINATOR EXCLUSIONS: Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure any time during the patient s history through the end of the measurement year: E84.0, E84.11, E84.19, E84.8, E84.9, J43.0, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J68.4, J96.00, J96.01, J96.02, J96.20, J96.21, J96.22, J98.2, J98.3 OR Any patients who had no asthma controller medications dispensed during the measurement year: G9808 OR Patients who use hospice services any time during the measurement period: G9809 Page 1 of 7

NUMERATOR: The number of patients who achieved a proportion of days (PDC) of at least 75% for their asthma controller medications during the measurement year Definition: PDC- The proportion of days covered by at least one asthma controller medication prescription, divided by the number of days in the treatment period. The treatment period is the period of time beginning on the earliest prescription dispensing date for any asthma controller medication during the measurement year through the last day of the measurement year. Table MMA-B: Asthma Controller Medications Description Prescriptions Antiasthmatic Dyphylline-guaifenesin Guaifenesin-theophylline combinations Antibody inhibitor Omalizumab Inhaled steroid Budesonide-formoterol Fluticasone-salmeterol Mometasone-formoterol combinations Inhaled corticosteroids Beclomethasone Budesonide Ciclesonide Flunisolide Fluticasone CFC free Mometasone Leukotriene modifiers Montelukast Zafirlukast Zileuton Mast cell stabilizers Cromolyn Methylxanthines Aminophylline Dyphylline Theophylline OR Numerator Options: Performance Met: Performance Not Met: Patient achieved a PDC of at least 75% for their asthma controller medication (G9810) Patient did not achieve a PDC of at least 75% for their asthma controller medication (G9811) RATIONALE: This measure assesses adherence to long term asthma controller medications in patients with persistent asthma. The improvement in quality envisioned by the use of this measure is increasing adherence to long term asthma controller medications in patients with persistent asthma. Increasing adherence to asthma controller medications can prevent and control asthma symptoms, improve quality of life, reduce the frequency and severity of asthma exacerbations, and potentially prevent a significant proportion of asthma related costs (hospitalizations, emergency room visits and missed work and school days) (Akinbami 2009; (National Heart, Lung, and Blood Institute [NHLBI]/National Asthma and Education Prevention Program [NAEPP] 2007). CLINICAL RECOMMENDATION STATEMENTS: Akinbami, L.J., J.E. Moorman, P.L. Garbe, E.J. Sondik. 2009. Status of Childhood Asthma in the United States, 1980 2007. Pediatrics 123;S131 45. doi: 10.1542/peds.2008 2233C. National Heart Lung and Blood Institute/National Asthma Education and Prevention Program. 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Washington (DC): National Heart Lung and Blood Institute (NHLBI), NIH Publication No. 07 4051. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (November 19, 2015). Page 2 of 7

Stillman, L. 2010. Living with Asthma in New England: Results from the 2006 BRFSS and Call back Survey. A report by the Asthma Regional Council of New England (February). http://www.hria.org/uploads/catalogerfiles/living withasthma innew england/hria_living_with_asthma_brfss_2010.pdf (November 19, 2015). COPYRIGHT: The measures and specifications were developed by and are owned by the National Committee for Quality Assurance ( NCQA ). NCQA holds a copyright in the measures and specifications and may rescind or alter these measures and specifications at any time. Users of the measures and specifications shall not have the right to alter, enhance or otherwise modify the measures and specifications, and shall not disassemble, recompile or reverse engineer the measures and specifications. Anyone desiring to use or reproduce the materials without modification for a non-commercial purpose may do so without obtaining any approval from NCQA. All commercial uses or requests for alteration of the measures and specifications must be approved by NCQA and are subject to a license at the discretion of NCQA. The measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided as is without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on measures and specifications or data reflective of performance under such measures and specifications. 2004-2017 National Committee for Quality Assurance, all rights reserved. Performance measures developed by NCQA for CMS may look different from the measures solely created and owned by NCQA. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. The American Medical Association holds a copyright to the CPT codes contained in the measures specifications. Page 3 of 7

Page 4 of 7

Page 5 of 7

2018 Registry Flow For Quality ID #444 NQF #1799: Medication Management for People with Asthma Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry data submission. 1. Start with Denominator 2. Check Patient Age: a. If Patient age is 5 thru 64 years equals No, do not include in Eligible Patient Population. Stop Processing. b. If Patient age is 5 thru 64 years equals Yes, proceed to check Diagnosis. 3. Check Diagnosis: a. If Diagnosis for Persistent Asthma as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Diagnosis for Persistent Asthma as Listed in the Denominator equals Yes, proceed to check Encounter Performed. 4. Check Encounter Performed: a. If Encounter Performed as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Encounter Performed as Listed in the Denominator equals Yes, proceed to Check Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure. 5. Check Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure: a. If Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure equals No, proceed to check No Asthma Controller Medications Dispensed During the Measurement Year. b. If Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure equals Yes, do not include in Eligible Patient Population. Stop Processing. 6. Check No Asthma Controller Medications Dispensed During the Measurement Year: a. If No Asthma Controller Medications Dispensed During the Measurement Year equals No, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period. b. If No Asthma Controller Medications Dispensed During the Measurement Year equals Yes, do not include in Eligible Patient Population. Stop Processing. 7. Check Patients Who Use Hospice Services Any Time During the Measurement Period: a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, include in Eligible Population. Page 6 of 7

b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Patient Population. Stop Processing. 8. Denominator Population: a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation. 9. Start Numerator 10. Check Patient Achieved a PDC of at Least 75% for Their Asthma Controller Medication: a. If Patient Achieved a PDC of at Least 75% for Their Asthma Controller Medication equals Yes, include in Data Completeness Met and Performance Met. b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 patients in the Sample Calculation. c. If Patient Achieved a PDC of at Least 75% for Their Asthma Controller Medication equals No, proceed to Patient Did Not Achieve a PDC of at Least 75% for Their Asthma Controller Medication. 11. Check Patient Did Not Achieve a PDC of at Least 75% for Their Asthma Controller Medication: a. If Patient Did Not Achieve a PDC of at Least 75% for Their Asthma Controller Medication equals Yes, include in Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation. c. If Patient Did Not Achieve a PDC of at Least 75% for Their Asthma Controller Medication equals No, proceed to Data Completeness Not Met. 12. Check Data Completeness Not Met: a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation. SAMPLE CALCULATIONS: Data Completeness= Performance Met (a=50 patients) + Performance Not Met (c=20 patients) = 70 patients = 87.50% Eligible Population / Denominator (d=80 patients) = 80 patients Performance Rate= Performance Met (a=50 patients) = 50 patients = 71.43% Data Completeness Numerator (70 patients) = 70 patients Page 7 of 7